免疫治疗联合局部治疗在老年晚期NSCLC患者中的疗效研究  

Study on the efficacy of immunotherapy combined with local treatment in elderly patients with advanced NSCLC

作　　者：卯云烨 王安 葛祥伟 翟今朝 李涛 汪进良 MAO Yunye;WANG An;GE Xiangwei;ZHAI Jinzhao;LI Tao;WANG Jinliang(Department of Oncology,Senior Department of Oncology,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Chinese PLA Medical School,Beijing 100853,China)

机构地区：[1]解放军总医院第五医学中心肿瘤医学部肿瘤内科,北京100071 [2]解放军医学院,北京100853

出　　处：《中国现代医生》2025年第11期39-41,共3页China Modern Doctor

摘　　要：目的 旨在评估免疫治疗联合局部治疗在老年晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中的疗效。方法 选取2018年1月至2022年10月就诊于解放军总医院的164例老年晚期NSCLC患者作为研究对象。根据是否接受过免疫治疗联合局部治疗分为局部治疗组(n=82)与无局部治疗组(n=82)。主要终点为总生存期(overall survival,OS),次要终点包括无进展生存(progression-free survival,PFS)、客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)。采用Cox比例风险模型评估预后因素。结果 局部治疗组患者的中位OS优于无局部治疗组。多因素分析结果表明,东部肿瘤协作组体力状况评分≥2分、存在骨转移和胸腔积液为独立预后不良因素。结论 免疫治疗联合局部治疗可提高老年晚期NSCLC患者的生存率。Objective To evaluate the efficacy of immunotherapy combined with local treatment in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 164 elderly patients with advanced NSCLC admitted in Chinese PLA General Hospital from January 2018 to October 2022 were selected as subjects.According to whether they have received immunotherapy combined with local treatment,they were divided into local treatment group(n=82)and non-local treatment group(n=82).The primary endpoint was overall survival(OS),while secondary endpoints included progression-free survival(PFS),objective response rate(ORR),and disease control rate(DCR).Cox proportional hazard models were applied to assess prognostic factors.Results The median OS in local treatment group was superior to non-local treatment group.Multivariate analysis confirmed that Eastern Cooperative Oncology Group performance status score≥2 points,bone metastasis,and pleural effusion were independent poor prognostic factors.Conclusion The combination of immunotherapy and local treatment may provide OS of elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 免疫治疗 局部治疗 老年患者 

分 类 号：R734.2[医药卫生—肿瘤]